Sepsis was associated with thrombocytopenia
Conditions
Interventions
Sponsors
Yantai Yuhuangding Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years, regardless of gender; 2.Platelet count <50×10^9/L prior to Romiplostim administration; 3.Diagnosed with sepsis; 4.Complete clinical data; 5.Voluntary participation in the study, signed informed consent form, and good compliance;
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating patients; 2.Patients with a known malignancy; 3.Known hypersensitivity to any component of the study drug; 4.History of immune disorders (e.g., idiopathic thrombocytopenic purpura); 5.Participation in any other clinical study of an investigational drug within 3 months prior to screening; 6.History of bone marrow, lung, liver, kidney, pancreas, or small intestine transplantation; 7.Any condition that interferes with the interpretation of study results or, in the investigator's opinion, makes the patient unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to response, defined as the time from treatment initiation to a platelet count increase to =75×10?/L; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of platelet sustained response within 2 weeks;The time required for platelets to rise to normal level >=100×10^9/L;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactLi Meifeng
Yantai Yuhuangding Hospital
Outcome results
None listed